Matthew D. Saybolt, MD, FACC
Matthew D. Saybolt, MD earned his degree in chemistry from Lafayette College and his medical doctorate from Rutgers Robert Wood Johnson Medical School. He went on to complete internal medicine residency at the Hospital of the University of Pennsylvania.
Following his training in internal medicine and a faculty appointment as chief resident, he completed his general cardiology fellowship at the Hospital of the University of Pennsylvania where he was chief fellow. He then remained at Penn to complete subspecialty training in interventional cardiology and structural heart disease where he was recognized by the university for his teaching and research. He has authored numerous scientific articles and editorials on the topics of transcatheter aortic valve replacement (TAVR), percutaneous coronary interventions, intravascular imaging, vulnerable plaque detection and health care quality improvement. He has over a dozen research presentations at national meetings including those of the of the American College of Cardiology, American Heart Association, and Transcatheter Cardiovascular Therapeutics. He remains actively involved in clinical research.
Dr. Saybolt specializes in minimally invasive therapies for the treatment of valvular and structural heart disease. These include transcatheter aortic valve replacement (TAVR), transcatheter mitral valve repair (MItraClip), closure of patent foramen ovale and atrial septal defect, transcatheter valve in valve therapy, paravalvular leak closure and alcohol septal ablation. He is also trained in the most advanced techniques for the treatment and management of coronary artery disease, pulmonary embolism and cardiogenic shock.
He is board certified in Internal Medicine and Cardiovascular Disease by the American Board of Internal Medicine. He is also board certified in Adult Echocardiography and board certified in Interventional Cardiology.
Dr. Saybolt is the Medical Director of Structural Heart Disease at Jersey Shore University Medical Center.
